Searching…
Jun 14, 2022 · Long-term RESONATE-2 data demonstrate sustained benefit with first-line ibrutinib treatment for CLL, including for patients with high-risk genomic features. These trials were registered at www.clinicalt...
Sep 1, 2024 · Conclusion: This final analysis of the landmark RESONATE-2study defines median PFS and demonstrates sustained OS benefit of continuous single-agent first-line ibrutinib treatment for patients with CLL/SL...
To report final long-term eficacy and safety analyses of first-line (1L) ibrutinib treatment with up to 10-years of follow-up from the RESONATE-2trial (NCT01722487)
RESONATE-2是当前唯一一项具有长期随访数据的全球、多中心、大规模、III期BTK抑制剂治疗CLL/SLL的随机对照研究，旨在探讨伊布替尼一线治疗CLL/SLL的疗效与安全性。 该研究的随访结果持续在ASH、EHA等重要学术会上公布，备受临床专家关注。
Aug 6, 2025 · 为解决老年CLL/SLL患者一线治疗选择难题，MD Anderson团队通过III期RESONATE-2研究（NCT01722487/46）对比伊布替尼与苯丁酸氮芥的长期疗效。
文献「RESONATE-2研究のCLL-076最終分析: 慢性リンパ球性白血病/小リンパ球性リンパ腫患者における第一選択イブルチニブ治療の10年までの追跡調査【JST機械翻訳】」の詳細情報です。
Dec 17, 2015 · We conducted a multicenter, open-label, randomized phase 3 trial (RESONATE-2; study number, PCYC-1115-CA) to evaluate the efficacy and safety of single-agent ibrutinib as compared with ...
